iatroX logo
brainstormaskiatroX
knowledge centreblog
Knowledge Centre / Prostate Specific Antigen (PSA) Testing

Prostate Specific Antigen (PSA) Testing

Guidelines and interpretation of PSA testing.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
UrologyOncologyGeneral Practice

Clinical Guidelines

CKS: Prostate cancer - Diagnosis - Assessment
National
CKS: Prostate cancer - Diagnosis - Screening for prostate cancer
National
NICE guideline [NG12]: Recommendations organised by site of cancer
National
Early Detection of Prostate Cancer: AUA/SUO Guideline
Local
ESMO Clinical Practice Guidelines: Prostate cancer: diagnosis, treatment and follow-up
Local
NICE guideline [NG12]: Suspected cancer: recognition and referral
Local
NICE NG12 and PCRMP Guidelines on PSA Testing
Local
US Preventive Services Task Force (USPSTF) Recommendation: Prostate Cancer: Screening
Local

Recent iatroX Q&As

  • What are the current NICE guidelines for the use of PSA testing in asymptomatic men?Updated: 8/22/2025
  • How should I interpret elevated PSA levels in a patient, and what follow-up investigations are recommended?Updated: 8/22/2025
  • What factors should be considered when discussing the risks and benefits of PSA testing with patients?Updated: 8/22/2025
  • When should I refer a patient with elevated PSA levels for urological assessment?Updated: 8/22/2025
  • How does age and family history influence the decision to perform PSA testing in men?Updated: 8/22/2025
askiatroX
privacytermshow it workscpdinsights
Download on the App StoreGet it on Google Play